Strong Rally and Market Context
On 3 December 2025, Venus Remedies touched an intraday peak of Rs.799.4, marking its highest price level in the past year and setting an all-time high for the company. This milestone comes after a three-day consecutive gain period during which the stock delivered a cumulative return of 14.22%. The day’s price movement included a 4.96% rise to the intraday high, with the stock outperforming its sector by 3.72% on the same day.
The broader market, represented by the Sensex, experienced a decline of 224.44 points, or 0.25%, closing at 84,926.20 after a flat opening. Despite this, the Sensex remains close to its own 52-week high, trading just 1.45% below the peak of 86,159.02. The index is supported by bullish moving averages, with the 50-day moving average positioned above the 200-day moving average, signalling underlying market strength.
Technical Indicators and Moving Averages
Venus Remedies is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests sustained buying interest and a positive trend in the stock’s price action. The alignment of these averages often indicates a robust upward momentum, which has been reflected in the stock’s recent performance.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Financial Performance Underpinning the Rally
Venus Remedies’ stock performance is supported by notable financial metrics. Over the past year, the company’s stock has delivered a return of 148.43%, significantly outpacing the Sensex’s 5.03% return during the same period. This substantial difference highlights the company’s strong market presence and growth trajectory within the Pharmaceuticals & Biotechnology sector.
The company’s net profit has shown a remarkable growth of 473.5%, with the latest six-month profit after tax (PAT) reported at Rs.29.73 crores, reflecting a growth of 528.54%. Profit before tax excluding other income (PBT less OI) for the quarter stands at Rs.24.78 crores, representing an extraordinary increase of 2073.68%. These figures underscore the company’s improving profitability and operational efficiency.
Valuation and Capital Structure
Venus Remedies maintains a low debt-to-equity ratio, averaging zero, which indicates a conservative capital structure with minimal reliance on debt financing. This financial prudence contributes to the company’s stability and reduces financial risk.
The company’s return on capital employed (ROCE) for the half-year period is recorded at 13.99%, while the return on equity (ROE) stands at 10.5%. These returns reflect effective utilisation of capital and shareholder funds. Additionally, the stock’s price-to-book value ratio is 1.7, suggesting a valuation that is reasonable relative to its peers and historical averages.
Long-Term and Recent Performance Comparison
Venus Remedies has demonstrated consistent market-beating performance not only in the recent year but also over longer periods. The stock has outperformed the BSE500 index over the last three years, one year, and three months, indicating sustained investor confidence and business growth. The company’s profits have risen by 183% over the past year, complementing the strong stock returns.
Want to dive deeper on Venus Remedies ? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Market Position and Risks
Despite its size and strong financials, Venus Remedies currently holds a minimal stake from domestic mutual funds, which have not allocated significant resources to the company. This limited participation may reflect a cautious stance or differing views on valuation or business prospects within certain institutional circles.
The stock’s 52-week low price was Rs.272.2, illustrating the considerable price appreciation achieved over the past year. This wide price range highlights the stock’s volatility and the scale of its recent upward movement.
Summary of Key Metrics
To summarise, Venus Remedies’ stock has reached a new high of Rs.799.4, supported by strong quarterly financial results, robust profitability growth, and favourable technical indicators. The company’s prudent capital structure and attractive valuation metrics further underpin this milestone achievement.
While the broader market experienced a slight downturn, Venus Remedies’ stock demonstrated resilience and momentum, reflecting its position within the Pharmaceuticals & Biotechnology sector and its operational progress over recent quarters.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
